JA-002

JA-002 is a potent, selective, and orally bioavailable small molecule inhibitor of autotaxin (ATX), also known as ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2). Developed by Janssen Research & Development, JA-002 targets the enzyme responsible for the conversion of lysophosphatidylcholine (LPC) into lysophosphatidic acid (LPA), a bioactive lipid mediator that plays a critical role in inflammation and tissue remodeling. By inhibiting ATX, JA-002 effectively reduces LPA levels, thereby attenuating pro-fibrotic signaling pathways that drive fibroblast activation, migration, and collagen deposition. Preclinical studies have demonstrated its efficacy in reducing lung fibrosis and improving respiratory function in animal models, positioning it as a significant lead candidate for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions.